epoetin-alfa and Inflammatory-Bowel-Diseases

epoetin-alfa has been researched along with Inflammatory-Bowel-Diseases* in 2 studies

Reviews

2 review(s) available for epoetin-alfa and Inflammatory-Bowel-Diseases

ArticleYear
Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.
    Expert opinion on biological therapy, 2017, Volume: 17, Issue:8

    While prescribing biosimilars to patients naive to a biologic treatment is a well-accepted practice, switching clinically stable patients from an originator to a biosimilar is an issue for clinicians. Well-designed clinical trials and real-world data which study the consequences of switching from an originator biologic treatment to its biosimilar alternative are limited, especially for monoclonal antibodies. Areas covered: A systematic literature review was conducted on PubMed to identify evidence of the consequences of switching from original biologics to biosimilars. References of included papers were also scrutinized. After a title-, abstract- and full text screening, out of the 153 original hits and 77 additional ones from screening the references, 58 papers (12 empirical papers, 5 systematic reviews and 41 non-empirical papers) were included. Expert opinion: Preventing patients on biologic medicines from switching to biosimilars due to anticipated risks seems to be disproportional compared to the expected cost savings and/or improved patient access. Indeed, it is the opinion of the authors that the concern of switching to biosimilars is overhyped.

    Topics: Anemia; Biosimilar Pharmaceuticals; Databases, Factual; Epoetin Alfa; Health Care Costs; Humans; Inflammatory Bowel Diseases; Kidney Failure, Chronic; Neoplasms; Red-Cell Aplasia, Pure; Rheumatic Diseases; Risk

2017
[Pathophysiological-based diagnosis and therapy of iron-deficient anaemia in inflammatory bowel disease].
    Zeitschrift fur Gastroenterologie, 2009, Volume: 47, Issue:2

    Anaemia is the most frequent extraenteric complication of inflammatory bowel disease (IBD, Crohn's disease and ulcerative colitis). A disabling complication of IBD, anaemia worsens the patient's general condition and quality of life, and increases hospitalization rates. The main types of anemia in IBD are iron deficiency anemia and anemia of chronic disease. The combination of the serum transferrin receptor with ferritin concentrations and inflammatory markers allows a reliable assessment of the iron status. Iron deficiency is usually treated with oral iron supplements. However, it is less effective in IBD and may lead to an increased inflammatory activity through the generation of reactive oxygen species. A systematic review of anemia in IBD, its pathogenetic features, epidemiology, diagnosis and therapy based on the evidence from recent studies will be the focus of this article.

    Topics: Administration, Oral; Anemia, Iron-Deficiency; Epoetin Alfa; Erythropoietin; Ferritins; Humans; Inflammatory Bowel Diseases; Injections, Intravenous; Iron Compounds; Recombinant Proteins; Time Factors; Transferrin

2009